As you can see, GNPX has been in a recent downtrend since mid October. Here's why that could all change soon.
No. 1 Potential GNPX Driver Indicator
Right now, according to Barchart, GNPX is displaying several oversold leaning technical indicators. Here's a sample:
- 9-Day Relative Strength Index = 30.24%
- 14-Day Relative Strength Index = 36.02%
When those two figures hit the low 30% range and delve into the upper 20% range, traders can view a profile as oversold, leading them to believe it is undervalued.
- 14-Day Raw Stochastic = 20.66%
- 14-Day Williams %R = 79.34%
When the Raw Stochastic nears single digits and the Williams %R nears the 90% level, traders can also view a profile as oversold and undervalued.
On top of all those oversold leaning technicals, Barchart is also reporting several technicals to be triggered as bullish. They are GNPX's:
Short Term Indicators
- 20 - 100 Day MACD Oscillator
- 20 - 200 Day MACD Oscillator
Medium Term Indicators
- 50 - 100 Day MACD Oscillator
- 50 - 150 Day MACD Oscillator
- 50 - 200 Day MACD Oscillator
Long Term Indicators
- 200 Day Moving Average
- 100 - 200 Day MACD Oscillator
It's an interesting mix of technicals, both bullish and oversold. Keep an eye on these closely as they may signal GNPX's next breakout if more become triggered.
No. 2 Potential GNPX Driver Indicator
James Molloy of Alliance Global Partners issued a new price target on April 22nd of 2020.
At the time, the stock was trading at $1.99. He initiated coverage and provided an $8.00 price target.
As of Wednesday's closing valuation of $3.09, GNPX is now displaying upside potential of 158% to that target.
Remember, it was just a few months back that we saw GNPX climb over the $7.00+ level when I brought it to your attention in February.
Could this stock's next big run be right around the corner?
Additionally, another analyst, Cosme Ordonez from Noble Financial has also pegged GNPX with a $5.00 target.
From Wednesday's close of $3.09, that provides GNPX with upside potential of 61%.
Now, I'm not saying that GNPX is going to be running to either of those targets today, but you need to be aware of the potential upside for this profile.
No. 3 Potential GNPX Driver Indicator
Genprex Added to Russell 3000® Index
Read the full article here.
Here's Why This News Could Change Everything
When an emerging growth company like GNPX joins the Russell 3000® Index, this can be a game-changing event that transforms a stock.
GNPX will now have an increased ability to attract institutional buying from hedge funds, banks, mutual funds, and 401 (k)'s.
No. 4 Potential GNPX Driver Indicator
National Institutes of Health (NIH) Awards Research Grant of $2.59Mn to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex
Read the full article here.
No. 5 Potential GNPX Driver Indicator
According to Yahoo Finance, GNPX currently has an approximate 31.73Mn shares in its float.
As we've seen in previous stock profiles, including this one when I brought it to you back in February (approximately 336% surge in roughly two weeks) and July (approximately 30% in 2 days), a low float can lead to explosive vertical surges in the short-term from volatility.
Biotech stocks can be very sensitive to news. One major development -- such as a positive result from a clinical trial -- and share prices can take off in a hurry.
Could the next big news coming from the GNPX camp be the spark to send share prices vertical?
More About The Company: Genprex, Inc.
From the company website:
Our mission is to develop life-changing gene therapies for patients with cancer and diabetes through unique, innovative science.
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases.
The company’s lead product candidate is GPX-001 (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC). The active ingredient in GPX-001 is the TUSC2 gene, a tumor suppressor gene. GPX-001 uses the company’s unique, proprietary Oncoprex™ nanoparticle delivery platform which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanoparticles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. In January 2020, the FDA granted Fast Track Designation for GPX-001 in combination with AstraZeneca’s Tagrisso® for the treatment of NSCLC. GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies.